Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ARWR stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mani Foroohar has given his Hold rating due to a combination of factors impacting Arrowhead Pharmaceuticals. The primary concern stems from the uncertainty surrounding the partnership with Sarepta Therapeutics (SRPT), which is facing potential revenue declines and risks related to its gene therapy product, Elevidys. This situation raises questions about SRPT’s commitment to its financial obligations towards Arrowhead, including equity investments and milestone payments.
Moreover, the potential for SRPT to sell its shares in Arrowhead to stabilize its own balance sheet could exert downward pressure on Arrowhead’s stock price. Additionally, if SRPT decides to terminate the partnership, Arrowhead could face renewed financial challenges, as the collaboration had previously alleviated concerns about its cash reserves. These uncertainties contribute to the cautious stance reflected in the Hold rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $14.50 price target.
ARWR’s price has also changed moderately for the past six months – from $19.760 to $14.710, which is a -25.56% drop .